Page last updated: 2024-11-06

cefoperazone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cefoperazone is a broad-spectrum cephalosporin antibiotic that is effective against a wide range of gram-negative and some gram-positive bacteria. It was first synthesized in the 1970s and is administered intravenously or intramuscularly. Cefoperazone works by inhibiting the synthesis of bacterial cell walls. It is often used to treat severe infections, including pneumonia, meningitis, and sepsis. Its importance lies in its broad-spectrum activity and its ability to reach therapeutic levels in various body fluids. Researchers continue to study cefoperazone for its potential use in treating infections caused by multidrug-resistant bacteria. '

Cefoperazone: Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cefoperazone : A semi-synthetic parenteral cephalosporin with a tetrazolyl moiety that confers beta-lactamase resistance. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID44187
CHEMBL ID507674
CHEBI ID3493
SCHEMBL ID37056
MeSH IDM0003720

Synonyms (75)

Synonym
(6r,7r)-7-{[(2r)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CHEBI:3493 ,
7beta-{[(2r)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl-3,4-didehydrocepham-4-carboxylic acid
cefoperazono
cefoperazonum
BIDD:GT0677
BRD-K02292852-335-03-1
peracef
CHEMBL507674
(6r,7r)-7-{[(2r)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1h-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
BPBIO1_000367
BSPBIO_000333
NCGC00179599-01
D07645
peracef [veterinary] (tn)
cefoperazone (inn)
PRESTWICK2_000327
PRESTWICK3_000327
C06883
cefoperazone
62893-19-0
DB01329
brn 0603333
(6r,7r)-7-((r)-2-(4-ethyl-2,3-dioxo-1-piperazinylcarboxamido)-2-(4-hydroxyphenyl)acetamido)-3-((1-methyl-1h-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure
einecs 263-749-4
cefoperazone [inn:ban]
cefoperazon
cp 52640
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)(4-hydroxyphenyl)acetyl)amino)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-(6-alpha,7-beta(r*)))-
PRESTWICK1_000327
PRESTWICK0_000327
SPBIO_002254
HMS2090M09
(6r,7r)-7-[[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
C-2485
bdbm50390999
cefoperazine
medocef
cefozon
unii-7u75i1278d
cefob
7u75i1278d ,
S1611
AKOS015895629
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)(4-hydroxyphenyl)acetyl)amino)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo, (6r-(6.alpha.,7.beta.(r*)))-
cefoperazone [mi]
(6r,7r)-7-((r)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2-(p-hydroxyphenyl)acetamido-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
cefoperazone [vandf]
cefoperazone [inn]
cefoperazone [who-dd]
HY-B0210
SCHEMBL37056
cefoperazone, antibiotic for culture media use only
pathozone
myticef
bioperazone
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2r)-2-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[[(1-methyl-1h-tetrazol-5-yl)thio]methyl]-8-oxo-, (6r,7r)-
C2768
mfcd00865067
DTXSID2022759
(6r,7r)-7-((r)-2-(4-ethyl-2,3-dioxopiperazine-1-carboxamido)-2-(4-hydroxyphenyl)acetamido)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SW198793-3
cefoperazone (cefobid)
cefoperazone,(s)
(6r,7r)-7-((r)-2-(4-ethyl-2,3-dioxopiperazine-1-carboxamido)-2-(4-hydroxyphenyl)acetamido)-3-((1-methyl-1h-tetrazol-5-ylthio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
AS-13298
Q2325775
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[(2r)-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3-[[(1-methyl-1h-tetrazol-5-yl)thio]methyl]-8-oxo-,(6r,7r)-
CCG-270325
(6r,7r)-7-[[(2r)-2-[[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl] amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[[(1-methyl-1h-tetrazol-5-yl) sulfanyl]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
EN300-6733818
(6r,7r)-7-[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetamido]-3-{[(1-methyl-1h-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
gtpl12025
Z2242164637
cefoperazone 1000 microg/ml in acetonitrile

Research Excerpts

Overview

Cefoperazone/sulbactam is a compound prepared from the third generation of cephalosporin and β-lactamase inhibitor. CefoperAZone is a third-generation cefalosporin that contains the N-methyl- thio-tetrazole (NMTT) side chain, which inhibits vitamin K-dependent carboxylation.

ExcerptReferenceRelevance
"Cefoperazone/sulbactam is a compound prepared from the third generation of cephalosporin and β-lactamase inhibitor."( Cefoperazone/sulbactam-induced hemolytic anemia.
Liu, LH; Sun, XM; Wang, HG; Wu, Q,
)
2.3
"Cefoperazone (CFP) is a potent antibacterial agent that is widely used for the treatment of bacterial infections. "( Structure-toxicity relationship of cefoperazone and its impurities to developing zebrafish by transcriptome and Raman analysis.
Han, Y; Hu, C; Qian, J; Wang, C; Zhang, J, 2017
)
2.17
"Cefoperazone is a â-lactam antimicrobial and Sulbactam is an irreversible â-lactamase inhibitor. "( In vitro activity of cefoperazone-sulbactam combination against gram negative bacilli.
Amatya, R; Baral, R; Bhattacharya, SK; Bhattarai, NR; Gurung, R; Gyawali, N; Khanal, B; Poudyal, N; Shrestha, S, 2012
)
2.14
"Cefoperazone is a third generation cephalosporin which is commonly used for bovine mastitis therapy. "( Proposal for agar disk diffusion interpretive criteria for susceptibility testing of bovine mastitis pathogens using cefoperazone 30μg disks.
Feßler, AT; Kaspar, H; Lindeman, CJ; Peters, T; Schwarz, S; Watts, JL, 2017
)
2.11
"Cefoperazone is a parenteral third generation cephalosporin which is active against many Gram positive and Gram negative organisms. "( Cefoperazone induced gastro-intestinal haemorrhage. A case report.
Bagbanci, B; Basaklar, AC; Demirogullari, B; Kale, N; Karabulut, R; Moralioğlu, S; Ozen, IO; Sonmez, K; Turkyilmaz, Z,
)
3.02
"Cefoperazone is a third-generation cefalosporin that contains the N-methyl- thio-tetrazole (NMTT) side chain, which inhibits vitamin K-dependent carboxylation. "( Severe INR elevation in a patient with choledocholithiasis receiving cefoperazone.
Alagozlu, H; Cindoruk, M; Unal, S, 2006
)
2.01
"Cefoperazone is a third generation cephalosporin antibiotic with a broad spectrum against gram-positive and gram-negative bacteria. "( Quantitative determination of unbound cefoperazone in rat bile using microdialysis and liquid chromatography.
Chang, YL; Chiou, SH; Chou, YC; Tsai, TH; Yen, CJ, 2007
)
2.05
"Cefoperazone is a new cephalosporin with a very wide spectrum of activity, including activity against Pseudomonas aeruginosa. "( Tentative interpretive standards for agar disk diffusion antimicrobial susceptibility testing of cefoperazone.
Badal, RE; Baker, CN; Barry, AL; Jones, RN; Thornsberry, C, 1982
)
1.92
"Cefoperazone is a new beta-lactam antibiotic that possesses a broad spectrum of activity against gram-positive and gram-negative organisms. "( Cefoperazone (Cefobid, Pfizer).
Lyon, JA, 1983
)
3.15
"Cefoperazone is a parenteral cephalosporin antibiotic that is pending approval by the U. "( Antimicrobial activity, pharmacokinetics, adverse reactions, and therapeutic indications of cefoperazone.
Funk, EA; Strausbaugh, LJ,
)
1.79
"Cefoperazone is a bactericidal beta-lactam, and its minimal inhibitory concentrations are influenced only by high inoculum concentrations of beta-lactamase-producing strains."( Cefoperazone: a review of its antimicrobial spectrum, beta-lactamase stability, enzyme inhibition, and other in vitro characteristics.
Barry, AL; Jones, RN,
)
2.3
"Cefoperazone appears to be an extremely useful injectable antibiotic for the treatment of respiratory tract infections in hospitalized patients."( Asian multicenter trial of cefoperazone in respiratory tract infection.
Chung, HY; Hsieh, WC; Matsumoto, K, 1984
)
1.29
"Cefoperazone is a new semisynthetic cephalosporin with excellent antibacterial activity. "( In vitro activity of a new semisynthetic cephalosporin: cefoperazone.
Auckenthaler, R; Waldvogel, FA, 1980
)
1.95
"Cefoperazone is a new piperazine cephalosporin derivative which has a broad antibacterial activity against aerobic and anaerobic gram-positive and gram-negative cocci and bacilli, including Pseudomonas aeruginosa. "( A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic.
Neu, HC, 1981
)
1.96
"Cefoperazone is a new cephalosporin with a very wide spectrum of antibacterial activity, including Enterobacteriaceae, Pseudomonas aeruginosa, staphylococci, streptococci (other than serological group D strains), Neisseria and Haemophilus species (including beta-lactamase positive strains) and some anaerobes. "( Cefoperazone: spectrum of antibacterial activity and disc diffusion testing.
Jones, RN; Thornsberry, C, 1981
)
3.15
"Cefoperazone promises to be an effective drug for the treatment of a wide spectrum of severe infections in hospitalised patients including those with impaired renal function."( Cefoperazone in the treatment of severe or complicated infections.
Bailey, RR; Bishop, V; Blake, E; Peddie, B; Reddy, J, 1981
)
2.43
"Cefoperazone is a new 'third generation' semisynthetic injectable cephalosporin. "( Cefoperazone: A review of its in vitro antimicrobial activity, pharmacological properties and therapeutic efficacy.
Avery, GS; Brogden, RN; Carmine, A; Heel, RC; Morley, PA; Speight, TM, 1981
)
3.15
"Cefoperazone is a semi-synthetic cefalosporine for parenteral use which has an excellent activity against a wide range of grampositive and gramnegative bacteria, especially Pseudomonas aeruginosa, Enterobacter, Proteus indole positive and Serratia marcescens. "( [Pharmacokinetic study of a cephalosporin: cefoperazone in patients with a Kehr drain].
Balant, L; Cochet, B; Fabre, J; Farquet, C; Marti, MC; Rohner, A; Rudhardt, M, 1982
)
1.97
"Cefoperazone is a third generation cephalosporin mainly excreted by the biliary route. "( [Effect of various types of liver diseases on the behavior of cefoperazone].
Châtelain, G; Dayer, P; Fabre, J; Malè, PJ; Rudhardt, M, 1983
)
1.95
"Cefoperazone is a third-generation semisynthetic injectable cephalosporin. "( Cefoperazone pharmacokinetics and sputum levels after single/multiple i.m. injections in bronchopneumopathic patients and bone, pulmonary and prostatic tissue penetration.
Biella, G; Braga, PC; Fraschini, F; Gagliardi, V; Manganelli, V; Paiola, G; Scaglione, F; Scarpazza, G; Villa, S, 1983
)
3.15
"Cefoperazone is a semisynthetic cephalosporin antibiotic containing a piperazine side chain, which results in antipseudomonal activity. "( The influence of chronic lobular hepatitis on pharmacokinetics of cefoperazone--a novel galactose single-point method as a measure of residual liver function.
Chang, CL; Hu, OY; Tang, HS, 1994
)
1.97
"Cefoperazone sodium is a broad spectrum third generation Cephalosporin recently introduced in India. "( Cefoperazone monotherapy for serious infections in hospitalized patients--an initial Indian experience.
Deshpande, AK; Kaundinya, DV; Shah, SS, 1995
)
3.18
"Cefoperazone is a semisynthetic cephalosporin of the 3rd generation (cefobid, Pfizer, USA). "( [Experience with using cefoperazone in cancer patients after bone marrow transplantation].
Afanas'ev, BV; Shmidt, AV; Zabelina, TS; Zubarevskaia, LS, 1992
)
2.04
"Cefoperazone-sulbactam is an attractive candidate for evaluation in the treatment of nosocomial infections due to aerobic gram-negative bacilli."( In-vitro susceptibility of cefoperazone-susceptible and -resistant gram-negative rods to cefoperazone plus sulbactam, other beta-lactams, aminoglycosides and quinolone.
Chandrasekar, PH; Sluchak, JA,
)
1.15
"Cefoperazone is a broad-spectrum cephalosporin that has been used extensively to treat infections in cancer patients. "( In vitro assessment of sulbactam plus cefoperazone in the treatment of bacteria isolated from cancer patients.
Bodey, GP; Ho, DH; Miller, P,
)
1.85
"Cefoperazone/sulbactam is a compound with excellent inhibitory and bactericidal activity against B."( In vitro comparison of cefoperazone/sulbactam with selected antimicrobials against 300 bacteroides isolates. Inhibitory activity and time-kill kinetic studies.
Gelfand, MS; Grogan, JT; Haas, MJ,
)
1.16
"Cefoperazone is an exception."( Pharmacokinetic study on adenomatous prostate tissue concentrations of cefoperazone. Clinical efficacy and patient tolerance of intramuscular cefoperazone treatment of chronic bacterial prostatitis.
Ammatuna, P; Cacciatore, M; Falletta, V; Formica, P; Gaglio, F; Melloni, D; Messina, G, 1989
)
1.23
"Cefoperazone is a third-generation cephalosporin that is active against a broad spectrum of gram-positive and gram-negative bacteria. "( Cefoperazone in the treatment of peritonitis in continuous ambulatory peritoneal dialysis patients.
Chan, AY; Ing, TS; Leehey, DJ; Reid, R, 1988
)
3.16
"Cefoperazone is a suitable alternative to combination antibiotic therapy for the treatment of hospital-acquired pneumonia."( Cefoperazone versus combination antibiotic therapy of hospital-acquired pneumonia.
Andriole, VT; Greco, T; Mangi, RJ; Ryan, J; Thornton, G, 1988
)
2.44
"Cefoperazone is a third generation cephalosporin which is secreted predominantly in bile. "( Biliary secretion of cefoperazone and its inter-relationship with bile acid transport in the rat.
Chapman, BA; Cowlishaw, M; Pattinson, NR, 1987
)
2.03
"Cefoperazone is a broad spectrum, third-generation cephalosporin with potential usefulness in treating endophthalmitis because of its in vitro activity against Gram-negative organisms. "( Retinal toxicity of intravitreal cefoperazone.
Bodé, DD; Harrison, JM; Kincaid, MC; O'Hara, MA; Perkins, MS, 1986
)
2

Effects

Cefoperazone (CPZ) has a broad antibacterial spectrum against Gram-positive, -negative aerobic and anaerobic organisms. It is also highly active against Pseudomonas sp.

ExcerptReferenceRelevance
"Cefoperazone (CPZ) has a broad antibacterial spectrum against Gram-positive, -negative aerobic and anaerobic organisms, it is also highly active against Pseudomonas sp. "( [Clinical effect of cephems: cefoperazone in the treatment of postoperative infections].
Beppu, T; Ichihara, T; Idegami, K; Ikei, S; Kanamitsu, T; Katabuchi, S; Mori, K; Morinaga, H; Sakamoto, K; Yamane, T, 1984
)
2
"Also cefoperazone has better sensitivity as compared to piperacillin + tazobactum."( Comparison of in vitro activities of ceftazidime, piperacillin-tazobactam, and cefoperazone-sulbactam, and the implication on empirical therapy in patients with cancer.
Biswas, S; Kelkar, R; Kurkure, P; Medhekar, A; Nair, R; Prabhash, K,
)
0.81
"Cefoperazone has found to have very wide spectrum of inhibition against frequently isolated microorganisms from clinical specimens."( [Antibacterial effect of cefoperazone].
Arslan, N; Fazli, SA; Ozbal, Y, 1984
)
1.29
"Cefoperazone has the usual antimicrobial spectrum of the cephalosporins, but the ratios of resistance to the various bacterial strains - even if they are problematic-are very low. "( [Investigation on the antimicrobial activity of cefoperazone (author's transl)].
Primavesi, CA, 1981
)
1.96
"Cefoperazone (CPZ) has a broad antibacterial spectrum against Gram-positive, -negative aerobic and anaerobic organisms, it is also highly active against Pseudomonas sp. "( [Clinical effect of cephems: cefoperazone in the treatment of postoperative infections].
Beppu, T; Ichihara, T; Idegami, K; Ikei, S; Kanamitsu, T; Katabuchi, S; Mori, K; Morinaga, H; Sakamoto, K; Yamane, T, 1984
)
2

Actions

ExcerptReferenceRelevance
"Cefoperazone, because of its high degree of protein binding and higher MIC90 , develops the least duration of time above the MIC90 for most pathogens."( Integration of selected pharmacologic and microbiologic properties of three new beta-lactam antibiotics: a hypothesis for rational comparison.
Drusano, GL; Moody, MR; Ryan, PA; Schimpff, SC; Standiford, HC,
)
0.85

Treatment

Cefoperazone treatment was associated with major changes in the faecal flora. Treatment with cefoperAZone/sulbactam was not associated with hypofibrinogenaemia (p = 0.681) but patients treated with it had a higher incidence of coagulopathy. Patients treated with the drug needed more blood products than those treated without.

ExcerptReferenceRelevance
"Cefoperazone-treated mice became colonized by C."( Diluted Fecal Community Transplant Restores Clostridioides difficile Colonization Resistance to Antibiotic-Perturbed Murine Communities.
Bishop, L; Colovas, J; Henry, A; Lesniak, NA; McBride, K; Schloss, PD; Taylor, A; Tomkovich, S, 2022
)
1.44
"Cefoperazone-treated mice were challenged with C."( Role of GM-CSF in the inflammatory cytokine network that regulates neutrophil influx into the colonic mucosa during Clostridium difficile infection in mice.
Falkowski, NR; Frank, CR; Huffnagle, GB; McDermott, AJ; McDonald, RA; Young, VB, 2014
)
1.12
"Cefoperazone treated mice challenged with C."( Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains.
Aronoff, DM; Bergin, II; Carlson, PE; Koumpouras, CC; Theriot, CM; Young, VB,
)
2.3
"The cefoperazone treatment was associated with major changes in the faecal flora."( Effect of cefoperazone on faecal flora.
Alestig, K; Carlberg, H; Nord, CE; Trollfors, B, 1983
)
1.15
"Treatment with cefoperazone/sulbactam was not associated with hypofibrinogenaemia (p = 0.681), but patients treated with cefoperazone/sulbactam had a higher incidence of coagulopathy (p = 0.009) and needed more blood products (p = 0.003) than those treated without cefoperazone/sulbactam."( Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients.
Fang, Q; Fang, XL; Hu, J; Lai, YX; Xiao, YH; Zheng, Y, 2020
)
0.9

Toxicity

ExcerptReferenceRelevance
" Adverse reactions occurred in 2 patients as systemic rush and fever."( [Clinical effectiveness of cefoperazone for respiratory infections of elderly patients, focusing on its safety on renal function].
Hirota, Y; Kohno, N; Kuriyama, T; Matsuda, Y; Morozumi, K; Nagai, H; Sato, T; Suzuki, T; Tanimoto, H; Yoneda, R, 1989
)
0.57
" In order to evaluate the importance of the different factors causing toxic effects, the authors studied the correlations between toxicity and antibiotic concentration and between toxicity and period of contact."( Toxic effects of some antibiotics on rabbit kidney cells.
Eandi, M; Santiano, M; Viano, I, 1983
)
0.27
" Because VCM has the adverse reaction of nephrotoxicity, we are apprehensive about using VCM with other antibiotics, which might increase this problem."( [Nephrotoxicity and drug interaction of vancomycin (2)].
Nakagawa, Y; Toyoguchi, T, 1996
)
0.29
" Mild or moderate side effect (allergic reaction including rash etc."( [Efficacy and safety of sulbactam/cefoperazone for hepato-biliary infections].
Amako, Y; Fujisaki, M; Hirano, M; Ishii, J; Itakura, M; Iwasa, T; Kako, M; Koyama, M; Mitamura, K; Nakaya, S; Nishio, T; Ohswawa, N; Ohyama, R; Okuda, K; Oohira, S; Saito, H; Shinagawa, N; Sugiyama, A; Takashima, S; Takeda, S; Ueda, M; Yamada, M; Yasuda, Y; Zeze, F, 1997
)
0.58
"To evaluate the utilization of antibacterial drugs and their adverse effects in patients admitted for respiratory disease based on medical record review."( [Survey of the utilization and adverse effects of antibacterial drugs in patients admitted for respiratory diseases].
Chen, Y; Xu, J; Zhang, Q; Zheng, P, 2005
)
0.33
" The drug utilization index (DUI) and daily cost of antibacterial drugs were calculated, with also assessment of the adverse effects in relation to the drug use."( [Survey of the utilization and adverse effects of antibacterial drugs in patients admitted for respiratory diseases].
Chen, Y; Xu, J; Zhang, Q; Zheng, P, 2005
)
0.33
"3 RMB, with a total of 14 cases with adverse drug effects recorded."( [Survey of the utilization and adverse effects of antibacterial drugs in patients admitted for respiratory diseases].
Chen, Y; Xu, J; Zhang, Q; Zheng, P, 2005
)
0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" In addition, both drugs were well-tolerated in this trial, with the number of drug-related adverse events being comparable."( Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia.
Liu, H; Liu, J; Xiong, S; Xiong, W; Xu, S; Xu, Y; Zhao, J, 2006
)
0.58
" No significant differences in adverse events were observed between groups."( Effectiveness and Safety of Generic Formulation of Cefoperazone/Sulbactam (Bacticep®) in Treatment of Infections at Siriraj Hospital.
Koomanachai, P; Thamlikitkul, V; Tongsai, S, 2016
)
0.69
" Previously, we found that both the C-7 and C-3 substituents of CFP are toxic functional groups, and two groups could affect gene expression in zebrafish embryos, thereby resulting in variable abnormal phenotypes."( Structure-toxicity relationship of cefoperazone and its impurities to developing zebrafish by transcriptome and Raman analysis.
Han, Y; Hu, C; Qian, J; Wang, C; Zhang, J, 2017
)
0.73
" The primary outcome was treatment success without modification, and the secondary outcomes were all-cause mortality and adverse events (AEs)."( Efficacy and safety of cefoperazone-sulbactam in empiric therapy for febrile neutropenia: A systemic review and meta-analysis.
Chang, SP; Lai, CC; Lan, SH; Lu, LC; Tang, HJ, 2020
)
0.87

Pharmacokinetics

The pharmacokinetic parameters of moxalactam were compared with those of cefoperazone and cefotaxime in normal volunteers in a crossover manner. No significant alteration in pharmacokinetics behavior was noted for cefOperazone or tobramycin alone or in combination.

ExcerptReferenceRelevance
" Pharmacokinetic parameters were determined by noncompartmental methods."( Effect of impaired renal function on the pharmacokinetics of coadministered cefoperazone and sulbactam.
Bawdon, RE; Castle, S; Norman, DC; Rho, JP; Smith, K, 1992
)
0.51
" The pharmacokinetic disposition of cefepime is similar to that of ceftazidime."( Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid.
Barriere, SL; Johnson, BL; Kalman, D, 1992
)
0.51
" Pharmacokinetic study was performed during a 8 hour period following one gram intravenous bolus."( [Does glycemic level influence the pharmacokinetics of an antibiotic (cefoperazone)?].
Albin, H; Aubertin, J; Demotes-Mainard, F; Gin, H; Magimel, S; Morlat, P,
)
0.37
" There were no significant differences between the pharmacokinetic variables calculated by statistical moment theory or compartmental analysis indicating central compartment output of cefoperazone."( Pharmacokinetics of single doses of cefoperazone given by the intravenous and intramuscular routes to unweaned calves.
Soback, S; Ziv, G, 1989
)
0.74
" The fitting of the individual serum concentration curves and the determination of pharmacokinetic constants were done according to a two-compartment model with the aid of nonlinear least-squares regression analysis on a programmable calculator TI 59."( Pharmacokinetics of cefoperazone in healthy volunteers.
Modr, Z; Morávek, J; Saudek, F, 1986
)
0.59
" We studied CPM killing kinetics using an in vitro model that simulates the pharmacokinetic profile observed in humans following a single intramuscular injection."( [Bactericidal activity of cefpiramide on P. aeruginosa using an in vitro pharmacokinetic simulation model].
Combes, T; Drigues, P; Labrousse, M; Mas, C; Roche, G, 1986
)
0.27
" In addition, the pharmacodynamic profile of this combination was determined by the use of mean bactericidal titers against selected bacterial strains."( Pharmacokinetics and pharmacodynamics of cefoperazone-sulbactam in patients on continuous ambulatory peritoneal dialysis.
Craig, WA; Johnson, CA; Leggett, JE; Reitberg, DP; Whall, TJ; Zimmerman, SW, 1988
)
0.54
" No cefoperazone pharmacokinetic parameters were appreciably altered by renal failure or hemodialysis, and there was no correlation between the total body clearance of cefoperazone and estimated creatinine clearance."( Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.
Marble, DA; Reitberg, DP; Schentag, JJ; Schultz, RW; Whall, TJ, 1988
)
1.16
" Mean estimates of cefoperazone maximal concentration in plasma (Cmax), area under the curve of drug concentration in plasma versus time (AUC), half-life (t 1/2), apparent volume of distribution by the area method (Varea), apparent volume of distribution at steady state (Vss), and total body clearance (CL) for day 1 (day 5) were 297."( Multiple-dose pharmacokinetics of intravenously administered cefoperazone and sulbactam when given in combination to infected, seriously ill, elderly patients.
Bachmann, KA; Jauregui, LE; Martin, ME; Reitberg, DP; Schwartz, JI, 1988
)
0.84
"The pharmacokinetic and microbiological properties of a new third generation cephalosporin, cefoperazone, when given by the intramammary route to the cow are described."( Pharmacokinetics of cefoperazone in the cow by the intramammary route and its effect on mastitis pathogens in vitro.
Gilbert, GA; Wilson, CD, 1986
)
0.81
" No significant alteration in pharmacokinetic behavior was noted for cefoperazone or tobramycin alone or in combination."( Pharmacokinetics of cefoperazone and tobramycin alone and in combination.
Flaherty, JF; Gambertoglio, JG; Guglielmo, BJ; LaFollette, G; Woods, TM, 1987
)
0.83
" The half-life at beta phase was higher in the elderly persons at both the 1- and 2-g doses but not significantly so."( Pharmacokinetics of cefoperazone in ambulatory elderly volunteers compared with young adults.
Deeter, RG; Hirschman, SZ; Mendelson, MH; Meyers, BR; Sarni, MT; Srulevitch-Chin, E, 1987
)
0.6
" The terminal serum half-life (2."( Pharmacokinetics of cefoperazone after single and multiple doses.
Dainelli, B; Ecari, U; La Rosa, F; Ripa, S; Ruffilli, MP, 1986
)
0.59
" Most pharmacokinetic parameters were also significantly altered early in the puerperium relative to those obtained 4 months later."( Pharmacokinetics of cefotaxime, moxalactam, and cefoperazone in the early puerperium.
Charles, D; Larsen, B, 1986
)
0.53
" in order to study its pharmacokinetic parameters."( Pharmacokinetic of sodium cefoperazone in calves.
Carli, S; Madonna, M; Montesissa, C; Sonzogni, O, 1986
)
0.57
"Limited pharmacokinetic data for cefoperazone are available from the parturient."( Pharmacokinetics of cefoperazone in the parturient.
Doughtie, CG; Feldman, S; Gonik, B; Pickering, LK, 1986
)
0.88
" The elimination half-life of both agents was about two to five times longer in pleural fluid than in serum."( Penetration and clearance of cefoperazone and moxalactam in pleural fluid.
Iida, K; Iwanaga, T; Nakanishi, H; Yamada, H; Yamaguchi, M, 1985
)
0.56
" The mean half-life of 240 min was one-half of that observed in 1- to 2-day-old infants but about twice that seen in adults."( Pharmacokinetic evaluation of cefoperazone in infants.
Evans, HE; Khan, AJ; Kumar, K; Rosenfeld, W; Schaeffer, HA; Varghese, M, 1985
)
0.56
"A pharmacokinetic study of cefoperazone on rats showed long half-life in serum and kidney."( A pharmacokinetic study of cefoperazone.
Fujita, HM; Fujita, K, 1985
)
0.86
" The half-life of indocyanine green was determined in each patient via ear oximetry."( Pharmacokinetics of multiple-dose cefoperazone in hemodialysis patients.
Bolton, WK; Richmond, JD; Scheld, WM; Spyker, DA, 1985
)
0.55
" CPZ is a new third generation cephalosporin which is mainly excreted into the bile and has serum half-life of about 2 hours."( [Pharmacokinetics of cefoperazone in liver diseases].
Kakiuchi, S; Kosaka, Y; Tagawa, S; Tameda, Y, 1985
)
0.59
" The serum CPZ level and half-life showed no significant trend except half-life showed a significant correlation with LAP."( [A pharmacokinetic study of cefoperazone during percutaneous transhepatic cholangial catheterization].
Hirakata, S; Kurane, R; Miyoshi, K; Oki, A; Sakai, H; Sakimura, K; Sato, T; Suwa, T; Suzuki, F; Toyama, N, 1985
)
0.56
" Pharmacokinetic parameters were determined by noncompartmental analysis."( Cefoperazone pharmacokinetics in preterm infants.
Bosso, JA; Chan, GM; Matsen, JM, 1983
)
1.71
" The mean peak concentration of cefoperazone in the serum of premature infants less than 33 weeks of gestational age, 159 (standard deviation, +/- 22) micrograms/ml, was higher than concentrations in premature infants 33 to 36 weeks of age and full-term infants (110 +/- 41 and 109 +/- 29 micrograms/ml, respectively)."( Pharmacokinetics of cefoperazone in full-term and premature neonates.
Batheja, R; Evans, HE; Jhaveri, RC; Khan, AJ; Rosenfeld, WN; Vohra, K, 1983
)
0.87
" In rabbit CSF, moxalactam had the greatest concentration and penetration, but rocephin had the longest half-life and duration of bactericidal activity."( Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis.
Loock, CA; McCracken, GH; Schaad, UB; Thomas, ML, 1981
)
0.5
"The pharmacokinetic parameters of moxalactam were compared with those of cefoperazone and cefotaxime in normal volunteers in a crossover manner."( Comparative pharmacokinetics of moxalactam, cefoperazone, and cefotaxime in normal volunteers.
Drusano, GL; McNamee, WB; Ryan, PA; Schimpff, SC; Standiford, HC; Tatem, B,
)
0.62
" Relevant pharmacokinetic parameters were calculated, using two- and three-compartment models."( Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.
Belmega, G; Borner, K; Jendroschek, T; Kemmerich, B; Koeppe, P; Lode, H, 1983
)
0.55
"Sulbactam, a new beta-lactamase inhibitor, has pharmacokinetic characteristics in humans similar to those of ampicillin and amoxicillin."( Pharmacokinetics of sulbactam in humans.
Foulds, G; Hayes, SL; Marshall, DC; McMahon, FG; O'Brien, MM; Stankewich, JP; Weidler, DJ, 1983
)
0.27
" The mean half-life after intramuscular injection was 108-154 min."( A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic.
Neu, HC, 1981
)
0.52
"19 liter/kg; dialysis), beta half-life (2."( Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency.
Bolton, WK; Sande, MA; Scheld, WM; Spyker, DA, 1981
)
0.59
" The results were compared with a pharmacokinetic study in healthy volunteers."( Biliary excretion and pharmacokinetics of cefoperazone in humans.
Belmega, D; Borner, K; Goertz, G; Jendroschek, T; Kemmerich, B; Koeppe, P; Lode, H, 1983
)
0.53
" Although most pharmacokinetic parameters did not differ significantly between normal subjects and patients with HSS, the serum beta half-life of cefoperazone was longer in patients with HSS compared to normal subjects (3."( Pharmacokinetics of cefoperazone in normal subjects and patients with hepatosplenic schistosomiasis.
Boscia, JA; Kaye, D; Kobasa, WD; Korzeniowski, OM; Levison, ME; Rocha, H, 1983
)
0.79
" Mean +/- SD values for cefoperazone steady-state volume of distribution (Vssd), elimination half-life (t1/2 beta), clearance (Cl), and area under the curve (AUC0-t) were 19."( Steady-state pharmacokinetics of cefoperazone and sulbactam in patients with acute appendicitis.
Danziger, LH; Occhipinti, DJ; Piscitelli, SC; Resnick, DJ; Rodvold, KA, 1994
)
0.88
" The changes in the concentration of CPZ were measured by employing MBPD and HPLC methods and experimental data were analyzed by using pharmacokinetic computer program."( [Experimental studies on the pharmacokinetics of cefoperazone (CPZ) injection under burn eschar].
Chen, B; Fang, J; Han, F, 1995
)
0.55
"1) The T1/2e of CPZ injection in subeschar region was longer and the Cmax was higher than that of intravenous route."( [Experimental studies on the pharmacokinetics of cefoperazone (CPZ) injection under burn eschar].
Chen, B; Fang, J; Han, F, 1995
)
0.55
" The half-life of cefaperazone, although not statistically significantly different, was prolonged in all patients during the postoperative period."( Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients.
Agarwala, S; Gayowski, T; Mirani, A; Muder, RR; Venkataramanan, R, 2002
)
0.64
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
" The pharmacokinetic parameters of cefoperazone in plasma of hospitalized volunteers were successfully estimated."( Voltammetric studies on the antibiotic drug cefoperazone quantification and pharmacokinetic studies.
Beltagi, AM; El-Attar, MA; Hammam, E, 2006
)
0.87
" Parameters relating to the pharmacokinetic interaction between PZFX and cefoperazone or azithromycin were estimated by a two-compartmental model."( Influence of cefoperazone and azithromycin on the pharmacokinetics of pazufloxacin in rats.
Hu, Q; Li, W; Lou, S,
)
0.73
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The method was successfully applied in a pharmacokinetic study of Sulperazon injection in six hospital-acquired pneumonia (HAP) patients."( Liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of cefoperazone and sulbactam in plasma and its application to a pharmacokinetic study.
Guo, B; Shi, Y; Wang, M; Yu, J; Zhang, J; Zhang, Y; Zhou, Y, 2010
)
0.58
" The bile drug concentration-time data were processed by software to figure out the pharmacokinetic parameters such as maximum concentration (C(max)), peak time (T(max)), half-life time (T(1/2)), clearance (CL) and apparent volume of distribution (VD)."( [Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential].
Lai, J; Li, S; Liang, L; Peng, B; Wang, Z; Zheng, J, 2014
)
0.4
"The aim of the research was an examination of potential impact of milk yield on the intercompartmental clearance - distribution clearance as well as determination of the variability of obtained pharmacokinetic parameters by the population approach using a two-compartmental structural model."( Impact of milk yield on pharmacokinetics of six intramammary drugs - a population approach.
Burmańczuk, A; Grabowski, T; Kowalski, C; Wojciechowska, B, 2018
)
0.48
"A model-based, open-label, opportunistic-sampling pharmacokinetic study was conducted in China."( Developmental population pharmacokinetics-pharmacodynamics and dosing optimization of cefoperazone in children.
Du, B; Huang, X; Jacqz-Aigrain, E; Kan, M; Li, X; Shen, AD; Shi, HY; Su, LQ; Tang, BH; Wang, K; Wang, RH; Wu, YE; Xu, BP; Zhao, W; Zheng, Y, 2020
)
0.78
"1% of hypothetical children treated with '40 mg/kg/day, q8h, IV drip 3 h' would reach the pharmacodynamic target."( Developmental population pharmacokinetics-pharmacodynamics and dosing optimization of cefoperazone in children.
Du, B; Huang, X; Jacqz-Aigrain, E; Kan, M; Li, X; Shen, AD; Shi, HY; Su, LQ; Tang, BH; Wang, K; Wang, RH; Wu, YE; Xu, BP; Zhao, W; Zheng, Y, 2020
)
0.78

Compound-Compound Interactions

The aim of this study was to compare the effectiveness of cefoperazone-sulbactam alone and combined with tigecycline in the treatment of multi-drug resistant acinetobacter baumannii pulmonary infection.

ExcerptReferenceRelevance
"The in vitro antimicrobial activity of ticarcillin (TICAR), mezlocillin (MEZLO), piperacillin (PIPER), cefoperazone (CPZ), cefotaxime (CTX) and ceftazidime (CAZ), alone and in combination with 8 micrograms/ml of sulbactam (SULB), was studied by agar dilution against TICAR resistant strains isolated in 8 hospitals over a period of 3 months in 1989 (747 enterobacteria, 110 Ps."( [In vitro activity of beta-lactam antibiotics in combination with sulbactam against enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter. Results of a multicenter study].
Acar, JF; Denis, F; Drugeon, H; Fleurette, J; Kazmierczak, A; Siebor, E; Sirot, J; Soussy, CJ; Thabaut, A, 1991
)
0.5
"Over a two year period 174 evaluable episodes of fever in neutropenic patients were treated in a randomized study comparing four beta-lactam antibiotics, each given in combination with netilmicin."( A randomized trial of empirical antibiotic therapy with one of four beta-lactam antibiotics in combination with netilmicin in febrile neutropenic patients.
Blacklock, H; Corringham, R; Devereux, S; Guimaraes, M; Hann, I; Hoffbrand, AV; Prentice, HG; Sage, R; Stirling, L; Trikka, E, 1988
)
0.27
"Cefpiramide and cefoperazone alone and in combination with gentamicin were compared for therapeutic efficacy against pseudomonal infections in normal mice and in mice made neutropenic by administration of cyclophosphamide."( Therapeutic efficacy of cefpiramide and cefoperazone alone and in combination with gentamicin against pseudomonal infections in neutropenic mice.
Fu, KP; Gregory, FJ; Hetzel, N; Hung, PP, 1986
)
0.88
"A broth dilution checkerboard synergy assay was used to assess the activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, in combination with tobramycin, against 38 strains of Pseudomonas aeruginosa."( Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa.
Drew, WL; Mintz, L, 1981
)
0.77
"Serum bactericidal activity (SBA) was studied in vitro after intravenous administration of cefoperazone alone or in combination with mezlocillin or amikacin to human volunteers."( Comparative study of the serum bactericidal activity of cefoperazone alone and in combination with amikacin or mezlocillin against gram-negative bacilli and Staphylococcus aureus.
Klastersky, J; Lagast, H; Standiford, H; Viollier, A,
)
0.6
" Therefore, the nephrotoxic effects and pharmacokinetics of VCM were examined in rabbits and compared with those in rabbits administered with VCM and other antibiotics."( [Nephrotoxicity and drug interaction of vancomycin (2)].
Nakagawa, Y; Toyoguchi, T, 1996
)
0.29
"The purpose of this prospective randomized study was to compare the efficacy and safety of imipenem and cefoperazone-sulbactam combined with vancomycin for the treatment of fever in neutropenic cancer patients."( Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients.
Abi-Said, D; Bodey, G; Raad, I; Rolston, K; Whimbey, E, 1996
)
0.89
"In the treatment of severe infections complicated to blood dyscrasia, the efficacy and usefulness of fosfomycin (FOM) in combination with sulbactam (SBT)/cefoperazone (CPZ) were compared between patients receiving FOM in the first followed by SBT/CPZ (Group A) and those receiving both drugs simultaneously (Group B)."( [Clinical efficacy of fosfomycin in combination with sulbactam/cefoperazone in the treatment of severe infections complicated to blood dyscrasia. Working Group of Kanto Combination Therapy for FOM + SBT/CPZ].
Ann, E; Bessho, M; Dan, K; Egashira, M; Fukuda, M; Hirai, H; Hirasawa, A; Hirashima, K; Hoshino, T; Hosoya, N; Ikeda, Y; Karasawa, M; Kawai, N; Kitamura, K; Kizaki, M; Miura, Y; Miyazawa, K; Nagasu, M; Naruse, T; Noguchi, M; Ohmine, K; Oshimi, K; Sugai, M; Takagi, S; Toyama, K, 1998
)
0.74
" Determination of MIC alone or in combination with cefazolin/oxacillin against Staphylococcus spp."( Antibacterial activity of allicin alone and in combination with beta-lactams against Staphylococcus spp. and Pseudomonas aeruginosa.
Cai, Y; Liang, BB; Pei, F; Wang, R, 2007
)
0.34
"We investigated in vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against Gram-negative bacilli."( In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli.
Kuo, HY; Lin, ML; Liu, CY; Wang, FD; Yen, YF, 2009
)
0.87
"The aim of this study was to investigate the in vitro activity of minocycline combined with cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii (CRAB)."( In vitro activity of minocycline alone and in combination with cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii.
Mao, Y; Pei, G; Sun, Y, 2012
)
0.84
" Moreover, tigecycline in combination with cefoperazone-sulbactam appeared to be more effective than tigecycline in combination with sulbactam against XDRAB."( In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii.
Bai, Y; Di, X; Liu, B; Liu, Y; Wang, J; Wang, R; Zhang, X, 2015
)
0.93
" Of studied drugs, daptomycin was the common element in the most active regimens when combined with doxycycline plus either beta-lactams (cefoperazone or carbenicillin) or an energy inhibitor (clofazimine)."( Drug combinations against Borrelia burgdorferi persisters in vitro: eradication achieved by using daptomycin, cefoperazone and doxycycline.
Auwaerter, PG; Feng, J; Zhang, Y, 2015
)
0.83
" SIGNIFICANCE AND IMPACT OF THE STUDY: Drug combination is an effective approach for the treatment of resistant bacterial infection."( In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant Acinetobacter baumannii.
Li, X; Lu, C; Sun, S; Wang, D; Wang, Y, 2020
)
0.56
"The aim of this study was to compare the effectiveness of cefoperazone-sulbactam alone and combined with tigecycline in the treatment of multi-drug resistant acinetobacter baumannii pulmonary infection."( Effectiveness of Cefoperazone-sulbactam alone and Combined with Tigecycline in the Treatment of Multi-drug Resistant Acinetobacter Baumannii Pulmonary Infection.
Chen, L; Deng, Y; Lv, Q; Ruan, J; Zhu, X, 2020
)
1.14
" She was administered cefoperazone and sulbactam sodium + metronidazole sodium chloride combined with morphine hydrochloride perioperatively, which caused a rash as an adverse side effect."( A case report of rash induced by cefoperazone sodium and sulbactam sodium plus metronidazole sodium chloride combined with morphine hydrochloride.
Huang, J; Jiang, C; Liu, Z; Zhu, X, 2020
)
1.15

Bioavailability

The pharmacokinetics and bioavailability of cefoperazone (CPZ) were studied following intravenous (IV) and intramuscular (IM) administration of single doses (30 mg/kg) to horses. Findings related to minimal inhibitory concentrations (MICs) for 90 bacterial strains isolated clinically from dogs.

ExcerptReferenceRelevance
" We conclude that until bioavailability studies are performed these three antibiotics should not be coadministered with nicardipine HCl."( The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection.
Alicea, M; Colucci, RD; Greenstein, R; Halpern, NA, 1989
)
0.28
"1 min and the estimated bioavailability after intramuscular administration was 76."( Pharmacokinetics of single doses of cefoperazone given by the intravenous and intramuscular routes to unweaned calves.
Soback, S; Ziv, G, 1989
)
0.55
"Cefpiramide (SR 95445) (CPM) is a new cephalosporin with activity against Pseudomonas and a good bioavailability following parenteral administration."( [Beta-lactamase induction in Pseudomonas aeruginosa by cefpiramide and 3 other antipyocyanic cephalosporins].
Combes, T; Drigues, P; Lanau, C; Roche, G; Salhi, A, 1986
)
0.27
" (area under the burn blister fluid concentration of drug-time curve between 0 and 8 hours after injection), absorption rate constant (ka) and therapeutic AUC (AUC where drug concentrations were above minimum effective concentration) of CPZ were calculated to be 194."( [Transfer of injected sulbactam/cefoperazone into burn blister fluid].
Aoyama, H; Izawa, Y; Okuda, J; Sugiyama, H; Tada, M, 1988
)
0.56
" The absolute bioavailability of the intraperitoneal dose was 61% for cefoperazone and 70% for sulbactam."( Pharmacokinetics and pharmacodynamics of cefoperazone-sulbactam in patients on continuous ambulatory peritoneal dialysis.
Craig, WA; Johnson, CA; Leggett, JE; Reitberg, DP; Whall, TJ; Zimmerman, SW, 1988
)
0.77
" The mean value of bioavailability (F) following the injection of both dosages was about 45%."( Pharmacokinetic of sodium cefoperazone in calves.
Carli, S; Madonna, M; Montesissa, C; Sonzogni, O, 1986
)
0.57
" After peritoneal instillation, the bioavailability was 63."( Pharmacokinetics of cefoperazone in patients undergoing chronic ambulatory peritoneal dialysis: clinical and pathophysiological implications.
Frey, B; Galeazzi, RL; Hodler, JE; Rudhardt, M; Seiler, AJ, 1984
)
0.59
"The pharmacokinetics and bioavailability of cefoperazone (CPZ) were studied following intravenous (IV) and intramuscular (IM) administration of single doses (30 mg/kg) to horses."( Pharmacokinetics of cefoperazone in horses.
Errecalde, JO; Mestorino, ON; Soraci, AL, 1996
)
0.88
") bioavailability of cefoperazone and cefamandole (20mg/kg) were investigated in dogs and the findings related to minimal inhibitory concentrations (MICs) for 90 bacterial strains isolated clinically from dogs."( Pharmacodynamics and pharmacokinetics of cefoperazone and cefamandole in dogs following single dose intravenous and intramuscular administration.
Anfossi, P; Carli, S; Montesissa, C; Villa, R; Zanoni, R, 2003
)
0.9

Dosage Studied

Sulbactam should predictably increase the antimicrobial spectrum and clinical effectiveness of cefoperazone against nosocomial and other pathogens such as the plasmid-containing enteric bacilli, Bacteroides species and Acinetobacter species.

ExcerptRelevanceReference
" The broad spectrum and the possibility of drug use without dosage modification facilitate the treatment of patients with various grades of renal failure."( [Effectiveness of Cefobid in pediatric practice].
Roszkowska-Blaim, M; Szymanik-Grzelak, H, 1992
)
0.28
" Agents with longer half lives allowing twice daily dosing (cefmetazole and cefotetan) were as effective and less expensive than multiple doses of short-acting agents."( Adjunctive antimicrobials in surgery of soft tissue infections: evaluation of cephalosporins and carbapenems.
Hopkins, JA; Lami, JL; Wilson, SE, 1991
)
0.28
" Hyperglycaemia was obtained by a reduction of one quarter of their usual insulin dosage and normoglycaemia by an artificial pancreas (Biostator GCIIS)."( [Does glycemic level influence the pharmacokinetics of an antibiotic (cefoperazone)?].
Albin, H; Aubertin, J; Demotes-Mainard, F; Gin, H; Magimel, S; Morlat, P,
)
0.37
" The findings suggest that the dosage of cefoperazone should be reduced in patients with liver cirrhosis and that the ujoviridin clearance test is a good indicator of impaired cefoperazone elimination."( Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test.
Modr, Z; Morávek, J; Saudek, F, 1989
)
1.99
" Therefore, sulbactam should predictably increase the antimicrobial spectrum and clinical effectiveness of cefoperazone against nosocomial and other pathogens such as the plasmid-containing enteric bacilli, Bacteroides species and Acinetobacter species, and possibly provide the opportunity to reduce dosage schedules for infecting species already susceptible to cefoperazone alone."( In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and beta-lactamase studies.
Barry, AL; Jones, RN; Thornsberry, C; Wilson, HW, 1985
)
0.76
" Dosage reduction of the antibiotic in advanced renal failure and repeated control of prothrombin time is advised."( Alteration of hemostasis associated with cefoperazone treatment.
Andrassy, K; Bechtold, H; Fritz, S; Koderisch, J; Sonntag, H,
)
0.4
"Eleven hospitalized patients with bacterial meningitis were treated with cefoperazone at daily dosage ranging between 3 and 8 g intravenously."( Cefoperazone therapy of bacterial meningitis: a preliminary report.
Coppola, L; Cristiano, P; Iannece, MD; Leonessa, V; Pempinello, R; Rescigno, C, 1987
)
1.95
" Only intraperitoneal dosing provided peak inhibitory and bactericidal titers in dialysate for all organisms tested."( Pharmacokinetics and pharmacodynamics of cefoperazone-sulbactam in patients on continuous ambulatory peritoneal dialysis.
Craig, WA; Johnson, CA; Leggett, JE; Reitberg, DP; Whall, TJ; Zimmerman, SW, 1988
)
0.54
" Serial blood and urine samples were collected from time zero to 12 h after dosing in normal subjects and from 0 to 72 h in renal patients."( Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.
Marble, DA; Reitberg, DP; Schentag, JJ; Schultz, RW; Whall, TJ, 1988
)
0.6
"Two dosing regimens of cefoperazone plus mezlocillin were compared in a prospective, randomized trial for therapy of febrile cancer patients."( Cefoperazone plus mezlocillin for empiric therapy of febrile cancer patients.
Bodey, GP; Fainstein, V; Jones, P; Riccardi, S; Rolston, K, 1988
)
2.03
"42 microgram/ml in acute phase patients in 1 g dosage group (acute group 1), 253."( [The penetration of cefoperazone into the cerebrospinal fluid in patients on acute or chronic stage].
Hara, K; Honda, E; Nishio, N; Shimamoto, H, 1988
)
0.6
" These sensitivities seem good enough for a clinical application of the method considering usual dosage levels of the drugs."( [High performance liquid chromatographic determination of astromicin and cefoperazone used in combination in blood samples].
Inoue, A; Kobayashi, S; Masuda, S; Takai, K, 1986
)
0.5
" From these findings, it is concluded that the present dosage regimen is efficient to prevent the postoperative infection after (semi-)radical hysterectomy."( [Penetration of cefoperazone into the exudate of the retroperitoneal space after (semi-)radical hysterectomy].
Izumi, S; Jeng, CH; Kojima, M; Kurihara, S; Nozawa, S; Tsai, DZ; Tsutsui, F, 1986
)
0.62
" Serum concentrations did not correlate with hypoprothrombinemia, but high levels throughout the dosing interval may have contributed to the excellent cure rate in this study."( Cefoperazone for empiric therapy in patients with impaired renal function.
Caputo, GM; Colao, DJ; Sattler, FR; Schoolwerth, AC, 1986
)
1.71
" More frequent (6 to 8 h) or higher (greater than or equal to 2 g) dosing appears to be necessary to achieve prolonged serum bactericidal activity against less susceptible isolates (MBC, greater than or equal to 2 to 8 micrograms/ml)."( Assessment of serum bactericidal activity after administration of cefoperazone, cefotaxime, ceftizoxime, and moxalactam to healthy subjects.
Barriere, SL; Mordenti, J; Ozasa, DC, 1985
)
0.51
" The mean dosage was 2 g twice a day."( [Multicenter study of cefoperazone in Austria].
Forenbacher, HH, 1985
)
0.58
" Scheduling of a 12-hour dosing regimen to coincide with the end of hemodialysis should obviate any need for alteration of dose."( Pharmacokinetics of multiple-dose cefoperazone in hemodialysis patients.
Bolton, WK; Richmond, JD; Scheld, WM; Spyker, DA, 1985
)
0.55
"To obtain useful informations for determining the optimal dosage of drugs in patients with impaired liver function, pharmacokinetics of cefoperazone (CPZ) was studied in healthy adults (normal control group) and 35 patients with liver disease (liver disease group)."( [Pharmacokinetics of cefoperazone in liver diseases].
Kakiuchi, S; Kosaka, Y; Tagawa, S; Tameda, Y, 1985
)
0.79
" Patients received either cefoperazone (14) intravenously or intramuscularly in a dose range from 2 to 8 g/day or cefotaxime (15) 1 to 2 g intravenous or intramusculary at dosing intervals of 6 to 8 h (total 3 to 8 g/day), depending on the severity of the disease."( A comparison of cefotaxime and cefoperazone in respiratory tract infections.
Garcia-Rodriguez, JA; Gomez-Garcia, AC, 1984
)
0.85
" SBT/CPZ was given to total 43 cases at a mean daily dosage of 80."( [Fundamental and clinical studies of sulbactam/cefoperazone in the pediatric field].
Fujimoto, T; Ishimoto, K; Koga, T; Motohiro, T; Nishiyama, T; Sakata, Y; Shimada, Y; Tanaka, K; Tominaga, K; Tomita, N, 1984
)
0.52
" Based on these results, SBT/CPZ is considered to be a highly effective antibiotic with clinical efficacy in obstetric and gynecological infections in the daily dosage of 2 g given in two divided doses."( [Experience with sulbactam/cefoperazone in the field of obstetrics and gynecology].
Hirai, S; Iida, S; Kohara, T; Matsui, Y; Noda, M, 1984
)
0.56
" Renal elimination accounts for only 20 percent of the agent's elimination; dosage modification is not necessary in decreased renal function."( Cefoperazone (Cefobid, Pfizer).
Lyon, JA, 1983
)
1.71
" Its long serum half-life, approximately two hours, permits a twelve hourly dosing schedule."( Antimicrobial activity, pharmacokinetics, adverse reactions, and therapeutic indications of cefoperazone.
Funk, EA; Strausbaugh, LJ,
)
0.35
" Major dosage modification should only be required with concomitant renal and hepatic dysfunction."( Pharmacokinetics of cefoperazone in patients with normal and impaired hepatic and renal function.
Craig, WA; Gerber, AU; Greenfield, RA,
)
0.45
" The usual dosage for pediatric patients was 25-50 mg/kg two or three times daily for about seven days."( Cefoperazone sodium in the treatment of serious bacterial infections in 2,100 adults and children: multicentered trials in Europe, Latin America, and Australasia.
Gordon, AJ; Phyfferoen, M,
)
1.57
" We conclude that, although mild to moderate impairment of cefoperazone excretion occurs in patients with hepatic disease, adjustment of dosage may be necessary only with concomitant renal insufficiency."( Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis.
Boscia, JA; Kaye, D; Kobasa, WD; Korzeniowski, OM; Levison, ME; Snepar, R, 1983
)
1.95
" Patients received one of the following three dosage regimens before collection of cerebrospinal fluid (CSF): one dose of 50 mg/kg (maximum, 2 g; group I), one dose of 100 mg/kg (maximum, 4 g; group II), three doses of 100 mg/kg each every 8 h (maximum, 4 g each dose; group III)."( Concentrations of cefoperazone in cerebrospinal fluid during bacterial meningitis.
Cable, D; Edralin, G; Overturf, G, 1983
)
0.6
" The mean concentrations 24 h after dosage were similar in all three groups, 13 to 17 micrograms/ml."( Pharmacokinetics of cefoperazone in full-term and premature neonates.
Batheja, R; Evans, HE; Jhaveri, RC; Khan, AJ; Rosenfeld, WN; Vohra, K, 1983
)
0.59
" Therefore, there is no need to relate the timing of blood (and urine) sampling for creatinine assay to dosage of these antibiotics."( Lack of interference of five new beta-lactam antibiotics with serum creatinine determination.
LeBel, M; Lewis, GP; Paone, RP, 1983
)
0.27
" Both the duration of time cefotaxime was above the MIC90 for the Enterobacteriaceae and the area under the concentration-time curve were significantly less because of its short elimination half-life, results indicating the need for more frequent dosing with cefotaxime than with moxalactam."( Integration of selected pharmacologic and microbiologic properties of three new beta-lactam antibiotics: a hypothesis for rational comparison.
Drusano, GL; Moody, MR; Ryan, PA; Schimpff, SC; Standiford, HC,
)
0.13
"A total of 187 physician investigators throughout the United States participated in a multicenter trial to evaluate the safety and efficacy of a twice daily dosage of cefoperazone sodium; 91 percent of patients received a dosage of 4 g or less of cefoperazone per day."( Multicenter clinical trial of cefoperazone sodium in the United States.
Barranco, SF; Cohen, MS; Washton, HE, 1984
)
0.75
" The dosage was 56 approximately 182 mg/kg/day, divided into 4 doses, and given intravenous injection."( [Clinical examination of cefoperazone in pediatrics (author's transl)].
Kagata, N; Matsuda, H; Niino, S; Yoshida, T, 1980
)
0.56
" The results raise the question of the desirability of cefoperazone dosage adjustment in patients with hepatic diseases."( [Pharmacokinetic study of a cephalosporin, cefoperazone, in liver failure].
Allaz, AF; Balant, L; Belaieff, J; Cochet, B; Fabre, J; Rudhardt, M, 1981
)
0.77
" Twice daily dosing with cefoperazone appears to be effective against numerous Gram-positive and Gram-negative bacteria in a variety of clinical infections."( Worldwide clinical experience with cefoperazone.
Craig, WA; Gerber, AU, 1981
)
0.84
" Since biliary excretion is normally the primary route of cefoperazone elimination, dosage modification should only be required in the presence of severe biliary obstruction or concomitant renal and hepatic dysfunction."( Pharmacokinetics of cefoperazone: a review.
Craig, WA; Gerber, AU, 1981
)
0.83
" A dosage schedule of 2 to 4 g daily will not lead to significant drug accumulation in the presence of severe renal failure."( Serum and urine concentrations of cefoperazone in severe chronic renal failure.
Bailey, RR; Blake, E; Peddie, B, 1981
)
0.54
" The daily dosage of cefoperazone ranged from 2 to 4 gm in two equally divided doses, and the daily dosage of amikacin ranged from 900 to 1,000 mg in two equally divided doses."( Comparative study of cefoperazone and amikacin.
Chang, ST; Chung, ES; Whang, CW, 1984
)
0.91
" After intravenous dosing CFP mean peak and 6-hr serum concentrations were 104."( Intraperitoneal and intravenous cefoperazone kinetics during continuous ambulatory peritoneal dialysis.
Hoppe-Seyler, G; Jansen, A; Keller, E; Pelz, K; Schollmeyer, P, 1984
)
0.55
" Serum levels of cefoperazone-sulbactam measured at one and three hours after dosing were consistent with earlier findings in normal volunteers."( Comparison of cefoperazone plus sulbactam with clindamycin plus gentamicin as treatment for intra-abdominal infections.
Bowen, K; Cayavec, P; Danko, LS; Greenberg, RN; Johnson, SB; Kearney, PA; Montazemi, R; Strodel, WE, 1994
)
0.99
" They were divided into three groups: the prevention group, in which cpz (cefoperazone) was immediately administered after the scald at the dose of 25 mg/kg with an interval of 1/12 h for a total of 4 doses; the treatment group, in which cpz was administered 48 th after the scald with the dosage same as above; control group in which cpz was not administered."( [The relationship between opportune administration of antibiotics and infection after burn injury: an experimental study].
Chen, B; Lu, L; Xu, M, 1994
)
0.52
" The disposition of cefoperazone/sulbactam is altered in this group of patients; however, these changes are not likely to warrant a dosage reduction."( Steady-state pharmacokinetics of cefoperazone and sulbactam in patients with acute appendicitis.
Danziger, LH; Occhipinti, DJ; Piscitelli, SC; Resnick, DJ; Rodvold, KA, 1994
)
0.89
" 4 patients with extended purulent wounds of the soft tissues and bone affections were treated with cefoperazon and local application of gentacicol (a dosage form of gentamicin based on collagen with prolonged action) which provided the clinical effect in all the cases."( [A trial of using Cefobid (cefoperazone) in treating infections of the skin and soft tissues].
Blatun, LA; Elagina, LV; Iakovlev, VP; Izotova, GN; Krutikov, MG; Puchkova, LS,
)
0.43
" Anti-microbial activity against a wide spectrum of organisms and twice daily dosage schedule qualify Cefoperazone as a single antibiotic of choice in severe infections in critically ill patients."( Cefoperazone monotherapy for serious infections in hospitalized patients--an initial Indian experience.
Deshpande, AK; Kaundinya, DV; Shah, SS, 1995
)
1.95
" Interference's from other antibiotics, drugs and dosage forms additives, in capsules and vials dosage forms, were investigated."( Selective spectrofluorimetric determination of phenolic beta-lactam antibiotics through the formation of their coumarin derivatives.
Belal, SF; El Walily, AF; Gazy, AA; Khamis, EF, 1999
)
0.3
" The concentrations of cefoperazone and sulbactam in serum and, when possible, in urine and bile collected over one dosing interval were measured by high-pressure liquid chromatography."( Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients.
Agarwala, S; Gayowski, T; Mirani, A; Muder, RR; Venkataramanan, R, 2002
)
0.95
" As these concentrations were below concentrations reported after single dosing studies and below those considered to be minimally inhibitory, death was presumed to have been caused by hypersensitivity and not an overdose."( A fatal case of suspected anaphylaxis with cefoperazone and sulbactam: LC-MS analysis.
Inoue, H; Iwata, Y; Kanamori, T; Kishi, T; Kuwayama, K; Miyaguchi, H; Tsujikawa, K, 2008
)
0.61
"Cefoperazone/sulbactam (CFP/SUL) is a β-lactam/β-lactamase inhibitor combination with little data available for the development of effective dosing guidelines during continuous renal replacement therapy."( Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.
An, R; Du, Z; Gao, C; Sun, Z; Tong, J; Yu, K, 2016
)
2.2
" For occasion 2, eight of nine patients achieved cefoperazone concentrations that were above the MIC for the entire dosing interval."( Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.
An, R; Du, Z; Gao, C; Sun, Z; Tong, J; Yu, K, 2016
)
1.01
" The significance of using drug combination is that it can reduce drug dosage requirements, reduce the toxic effects of agents and prevent or delay the emergence of drug resistance."( In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant Acinetobacter baumannii.
Li, X; Lu, C; Sun, S; Wang, D; Wang, Y, 2020
)
0.56
" Hence, there is a strong rationale to individualize anti-infective dosing in these patients by using therapeutic drug monitoring (TDM)."( Determination of Total and Unbound Meropenem, Imipenem/Cilastatin, and Cefoperazone/Sulbactam in Human Plasma: Application for Therapeutic Drug Monitoring in Critically Ill Patients.
Dang, ZL; Li, B; Qin, HY; Rao, Z; Wei, YH; Wu, XA; Zhu, L, 2020
)
0.79
"To evaluate the population pharmacokinetics of cefoperazone in children and establish an evidence-based dosing regimen using a developmental pharmacokinetic-pharmacodynamic approach in order to optimize cefoperazone treatment."( Developmental population pharmacokinetics-pharmacodynamics and dosing optimization of cefoperazone in children.
Du, B; Huang, X; Jacqz-Aigrain, E; Kan, M; Li, X; Shen, AD; Shi, HY; Su, LQ; Tang, BH; Wang, K; Wang, RH; Wu, YE; Xu, BP; Zhao, W; Zheng, Y, 2020
)
1.04
"For cefoperazone, population pharmacokinetics were evaluated in children and an appropriate dosing regimen was developed based on developmental pharmacokinetics-pharmacodynamics."( Developmental population pharmacokinetics-pharmacodynamics and dosing optimization of cefoperazone in children.
Du, B; Huang, X; Jacqz-Aigrain, E; Kan, M; Li, X; Shen, AD; Shi, HY; Su, LQ; Tang, BH; Wang, K; Wang, RH; Wu, YE; Xu, BP; Zhao, W; Zheng, Y, 2020
)
1.34
" Locally applied Layer-by-Layer (LbL) microcarriers transporting a low, but efficient dosage of active agents directly into the inflamed tissue offer a gentle therapy option."( Dual Transport of Active Substances with a Layer-by-Layer-Based Drug Delivery System to Terminate Inflammatory Processes.
Brueckner, M; Hollenbach-Latzko, S; Reibetanz, U, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
cephalosporinA class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 6Rattus norvegicus (Norway rat)IC50 (µMol)298.00000.50000.50000.5000AID680340
Solute carrier family 22 member 6Rattus norvegicus (Norway rat)Ki480.00001.60005.744010.0000AID681363
Glutathione reductase, mitochondrialHomo sapiens (human)Ki28.72000.80003.45006.1000AID1803292
Solute carrier family 22 member 6Homo sapiens (human)Ki0.21000.03003.20437.8200AID681377
Solute carrier family 22 member 8Homo sapiens (human)Ki1.89000.04004.22979.0000AID681373
Solute carrier family 22 member 11Homo sapiens (human)Ki2.80000.20002.57716.1500AID681569
Solute carrier family 22 member 8Rattus norvegicus (Norway rat)Ki670.00003.09005.54009.1000AID681344
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-lactamase Citrobacter freundiiKm5.00005.00007.00009.0000AID405084
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (65)

Processvia Protein(s)Taxonomy
cellular oxidant detoxificationGlutathione reductase, mitochondrialHomo sapiens (human)
cellular response to oxidative stressGlutathione reductase, mitochondrialHomo sapiens (human)
glutathione metabolic processGlutathione reductase, mitochondrialHomo sapiens (human)
cell redox homeostasisGlutathione reductase, mitochondrialHomo sapiens (human)
temperature homeostasisGlutathione peroxidase 1Homo sapiens (human)
endothelial cell developmentGlutathione peroxidase 1Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGlutathione peroxidase 1Homo sapiens (human)
triglyceride metabolic processGlutathione peroxidase 1Homo sapiens (human)
glutathione metabolic processGlutathione peroxidase 1Homo sapiens (human)
sensory perception of soundGlutathione peroxidase 1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressGlutathione peroxidase 1Homo sapiens (human)
response to xenobiotic stimulusGlutathione peroxidase 1Homo sapiens (human)
response to symbiotic bacteriumGlutathione peroxidase 1Homo sapiens (human)
UV protectionGlutathione peroxidase 1Homo sapiens (human)
response to hormoneGlutathione peroxidase 1Homo sapiens (human)
response to selenium ionGlutathione peroxidase 1Homo sapiens (human)
response to gamma radiationGlutathione peroxidase 1Homo sapiens (human)
arachidonic acid metabolic processGlutathione peroxidase 1Homo sapiens (human)
lipoxygenase pathwayGlutathione peroxidase 1Homo sapiens (human)
response to estradiolGlutathione peroxidase 1Homo sapiens (human)
response to hydroperoxideGlutathione peroxidase 1Homo sapiens (human)
response to vitamin EGlutathione peroxidase 1Homo sapiens (human)
regulation of mammary gland epithelial cell proliferationGlutathione peroxidase 1Homo sapiens (human)
cellular response to oxidative stressGlutathione peroxidase 1Homo sapiens (human)
response to nicotineGlutathione peroxidase 1Homo sapiens (human)
epigenetic regulation of gene expressionGlutathione peroxidase 1Homo sapiens (human)
vasodilationGlutathione peroxidase 1Homo sapiens (human)
response to hydrogen peroxideGlutathione peroxidase 1Homo sapiens (human)
hydrogen peroxide catabolic processGlutathione peroxidase 1Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processGlutathione peroxidase 1Homo sapiens (human)
skeletal muscle tissue regenerationGlutathione peroxidase 1Homo sapiens (human)
blood vessel endothelial cell migrationGlutathione peroxidase 1Homo sapiens (human)
fat cell differentiationGlutathione peroxidase 1Homo sapiens (human)
myoblast differentiationGlutathione peroxidase 1Homo sapiens (human)
cell redox homeostasisGlutathione peroxidase 1Homo sapiens (human)
fibroblast proliferationGlutathione peroxidase 1Homo sapiens (human)
skeletal muscle fiber developmentGlutathione peroxidase 1Homo sapiens (human)
neuron apoptotic processGlutathione peroxidase 1Homo sapiens (human)
myoblast proliferationGlutathione peroxidase 1Homo sapiens (human)
response to folic acidGlutathione peroxidase 1Homo sapiens (human)
biological process involved in interaction with symbiontGlutathione peroxidase 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionGlutathione peroxidase 1Homo sapiens (human)
heart contractionGlutathione peroxidase 1Homo sapiens (human)
angiogenesis involved in wound healingGlutathione peroxidase 1Homo sapiens (human)
regulation of proteasomal protein catabolic processGlutathione peroxidase 1Homo sapiens (human)
cellular response to glucose stimulusGlutathione peroxidase 1Homo sapiens (human)
negative regulation of release of cytochrome c from mitochondriaGlutathione peroxidase 1Homo sapiens (human)
cellular oxidant detoxificationGlutathione peroxidase 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsGlutathione peroxidase 1Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayGlutathione peroxidase 1Homo sapiens (human)
positive regulation of supramolecular fiber organizationGlutathione peroxidase 1Homo sapiens (human)
glutathione transportMicrosomal glutathione S-transferase 1Homo sapiens (human)
cellular response to lipid hydroperoxideMicrosomal glutathione S-transferase 1Homo sapiens (human)
cellular oxidant detoxificationMicrosomal glutathione S-transferase 1Homo sapiens (human)
monoatomic anion transportSolute carrier family 22 member 6Homo sapiens (human)
response to organic cyclic compoundSolute carrier family 22 member 6Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 6Homo sapiens (human)
organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 6Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 6Homo sapiens (human)
renal tubular secretionSolute carrier family 22 member 6Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 8Homo sapiens (human)
response to toxic substanceSolute carrier family 22 member 8Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 8Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 8Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 8Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 11Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 11Homo sapiens (human)
organic anion transportSolute carrier family 22 member 11Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 11Homo sapiens (human)
urate metabolic processSolute carrier family 22 member 11Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 11Homo sapiens (human)
xenobiotic metabolic processSolute carrier family 22 member 7Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 7Homo sapiens (human)
organic anion transportSolute carrier family 22 member 7Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 7Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 22 member 7Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (19)

Processvia Protein(s)Taxonomy
electron transfer activityGlutathione reductase, mitochondrialHomo sapiens (human)
NADP bindingGlutathione reductase, mitochondrialHomo sapiens (human)
glutathione-disulfide reductase (NADPH) activityGlutathione reductase, mitochondrialHomo sapiens (human)
flavin adenine dinucleotide bindingGlutathione reductase, mitochondrialHomo sapiens (human)
glutathione peroxidase activityGlutathione peroxidase 1Homo sapiens (human)
protein bindingGlutathione peroxidase 1Homo sapiens (human)
SH3 domain bindingGlutathione peroxidase 1Homo sapiens (human)
phospholipid-hydroperoxide glutathione peroxidase activityGlutathione peroxidase 1Homo sapiens (human)
glutathione transferase activityMicrosomal glutathione S-transferase 1Homo sapiens (human)
glutathione peroxidase activityMicrosomal glutathione S-transferase 1Homo sapiens (human)
protein bindingMicrosomal glutathione S-transferase 1Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
protein bindingSolute carrier family 22 member 6Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
chloride ion bindingSolute carrier family 22 member 6Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 8Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 11Homo sapiens (human)
protein bindingSolute carrier family 22 member 11Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
protein bindingSolute carrier family 22 member 7Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
mitochondrial matrixGlutathione reductase, mitochondrialHomo sapiens (human)
cytosolGlutathione reductase, mitochondrialHomo sapiens (human)
external side of plasma membraneGlutathione reductase, mitochondrialHomo sapiens (human)
extracellular exosomeGlutathione reductase, mitochondrialHomo sapiens (human)
cytosolGlutathione reductase, mitochondrialHomo sapiens (human)
mitochondrionGlutathione reductase, mitochondrialHomo sapiens (human)
Lewy bodyGlutathione peroxidase 1Homo sapiens (human)
cytoplasmGlutathione peroxidase 1Homo sapiens (human)
mitochondrionGlutathione peroxidase 1Homo sapiens (human)
mitochondrial matrixGlutathione peroxidase 1Homo sapiens (human)
cytosolGlutathione peroxidase 1Homo sapiens (human)
mitochondrionGlutathione peroxidase 1Homo sapiens (human)
cytosolGlutathione peroxidase 1Homo sapiens (human)
mitochondrionMicrosomal glutathione S-transferase 1Homo sapiens (human)
mitochondrial outer membraneMicrosomal glutathione S-transferase 1Homo sapiens (human)
peroxisomal membraneMicrosomal glutathione S-transferase 1Homo sapiens (human)
endoplasmic reticulumMicrosomal glutathione S-transferase 1Homo sapiens (human)
endoplasmic reticulum membraneMicrosomal glutathione S-transferase 1Homo sapiens (human)
plasma membraneMicrosomal glutathione S-transferase 1Homo sapiens (human)
membraneMicrosomal glutathione S-transferase 1Homo sapiens (human)
azurophil granule membraneMicrosomal glutathione S-transferase 1Homo sapiens (human)
mitochondrionMicrosomal glutathione S-transferase 1Homo sapiens (human)
plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
caveolaSolute carrier family 22 member 6Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 6Homo sapiens (human)
protein-containing complexSolute carrier family 22 member 6Homo sapiens (human)
plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 8Homo sapiens (human)
plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
external side of plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 11Homo sapiens (human)
cytosolSolute carrier family 22 member 7Homo sapiens (human)
plasma membraneSolute carrier family 22 member 7Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 7Homo sapiens (human)
membraneSolute carrier family 22 member 7Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 7Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (205)

Assay IDTitleYearJournalArticle
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1548095Antimicrobial activity against Escherichia coli assessed as inhibition of microbial growth incubated for 16 hrs by microdilution method2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Novel Stapling by Lysine Tethering Provides Stable and Low Hemolytic Cationic Antimicrobial Peptides.
AID325444Antibacterial activity against Escherichia coli K12 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID543421Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 by disk diffusion method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID325449Antibacterial activity against Staphylococcus aureus ATCC 3556 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID1885893Antibacterial activity against Escherichia coli BNCC 133264 measured after 16 hrs by microdilution assay2022Journal of medicinal chemistry, 08-11, Volume: 65, Issue:15
Lysine-Tethered Stable Bicyclic Cationic Antimicrobial Peptide Combats Bacterial Infection in Vivo.
AID562220Antimicrobial activity against Desulfovibrio sp. by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Susceptibilities of 23 Desulfovibrio isolates from humans.
AID543426Antimicrobial activity against Escherichia coli XL-1 Blue harboring beta-lactamase CTx-M-64transconjugant by disk diffusion method in presence of beta-lactamase inhibitor Sulbactam2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID519743Antibacterial activity against Klebsiella pneumoniae INSRA1229 harboring SHV-72 Ile8Phe, Ala146Val, and Lys234Arg mutations by agar dilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID520788Antibacterial activity against beta-lactamase KPC-2 producing Klebsiella pneumoniae isolate K1 to K9 in presence of Sulbactam by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID678797TP_TRANSPORTER: inhibition of PGF2alpha in OAT2-S2 cells2003European journal of pharmacology, Mar-28, Volume: 465, Issue:1-2
Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics.
AID562218Antimicrobial activity against Desulfovibrio fairfieldensis in presence of Sulbactam by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Susceptibilities of 23 Desulfovibrio isolates from humans.
AID567585Antimicrobial activity against Acinetobacter baumannii by broth dilution method in presence of beta-lactamase inhibitor Sulbactam2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.
AID405085Ratio of Kcat to Km of Citrobacter freundii PER2 beta lactamase2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Biochemical characterization of PER-2 and genetic environment of blaPER-2.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1211554Biliary excretion index in sandwich cultured Sprague-Dawley rat hepatocytes after 15 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1211878Unbound biliary clearance in iv dosed rat2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1548094Antimicrobial activity against Listeria monocytogenes assessed as inhibition of microbial growth incubated for 16 hrs by microdilution method2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Novel Stapling by Lysine Tethering Provides Stable and Low Hemolytic Cationic Antimicrobial Peptides.
AID562219Antimicrobial activity against Desulfovibrio sp. in presence of Sulbactam by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Susceptibilities of 23 Desulfovibrio isolates from humans.
AID660261Ratio of MIC for wild type Escherichia coli JC7623 to MIC for acrAB-deficient Escherichia coli JZM1202012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID1219875Inhibition of recombinant human ABCC4 expressed in baculovirus infected insect Sf21 cell plasma membrane vesicles assessed as inhibition of transporter-mediated [3H]-estradiol-17beta-glucuronide uptake by liquid scintillation counting analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Oral availability of cefadroxil depends on ABCC3 and ABCC4.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID325445Antibacterial activity against Escherichia coli C921-61 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1211555In vitro apparent biliary clearance in sandwich cultured Sprague-Dawley rat hepatocytes after 15 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID562224Antimicrobial activity against Desulfovibrio piger by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Susceptibilities of 23 Desulfovibrio isolates from humans.
AID1885890Antibacterial activity against Listeria monocytogenes measured after 16 hrs by microdilution assay2022Journal of medicinal chemistry, 08-11, Volume: 65, Issue:15
Lysine-Tethered Stable Bicyclic Cationic Antimicrobial Peptide Combats Bacterial Infection in Vivo.
AID519737Antibacterial activity against Escherichia coli DH5alpha expressing Klebsiella pneumoniae beta-lactamase SHV-1 by agar dilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID521437Ratio of induction of xylE gene expression in Stenotrophomonas maltophilia isolate KJ deficient in L1 beta lactamase gene to induction of xylE gene expression in Stenotrophomonas maltophilia isolate KJ deficient in L2 beta lactamase gene assessed as catec2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID1548092Antimicrobial activity against Staphylococcus aureus assessed as inhibition of microbial growth incubated for 16 hrs by microdilution method2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Novel Stapling by Lysine Tethering Provides Stable and Low Hemolytic Cationic Antimicrobial Peptides.
AID65230Minimum inhibitory concentration for inhibition of [14C]- Pen G binding to Escherichia coli UB1005.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Dual-action cephalosporins: cephalosporin 3'-quinolone carbamates.
AID521426Antibacterial activity against Stenotrophomonas maltophilia isolate KJ deficient in L1 beta lactamase gene by Etest2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID520789Antibacterial activity against beta-lactamase KPC-2 producing Klebsiella pneumoniae isolate K10 in presence of Sulbactam by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID519740Antibacterial activity against Escherichia coli DH5alpha expressing Klebsiella pneumoniae beta-lactamase SHV-72 by agar dilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID521427Antibacterial activity against Stenotrophomonas maltophilia isolate KJ deficient in L2 beta lactamase gene by Etest2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID1211857Unbound biliary clearance in human at 2 gm, iv after 24 hrs by T-tube method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID325447Antibacterial activity against Staphylococcus aureus N315 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID520081Antimicrobial activity against aheB deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method in presence of 64 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID678819TP_TRANSPORTER: inhibition of PGF2alpha in OAT2-S2 cells2003European journal of pharmacology, Mar-28, Volume: 465, Issue:1-2
Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics.
AID681373TP_TRANSPORTER: inhibition of Estrone sulfate uptake in OAT3-expressing S2 cells2002European journal of pharmacology, Mar-08, Volume: 438, Issue:3
Interaction of human organic anion transporters with various cephalosporin antibiotics.
AID155831The compound was evaluated for the inhibition of [14C]- Pen G binding to Escherichia coli UB1005 PBP1b 90 kDa.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Dual-action cephalosporins: cephalosporin 3'-quinolone carbamates.
AID562231Antimicrobial activity against Desulfovibrio piger in presence of Sulbactam by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Susceptibilities of 23 Desulfovibrio isolates from humans.
AID562227Antimicrobial activity against Desulfovibrio desulfuricans Essex 6 in presence of Sulbactam by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Susceptibilities of 23 Desulfovibrio isolates from humans.
AID681344TP_TRANSPORTER: inhibition of Estrone sulfate uptake in OAT3-expressing S2 cells2002Life sciences, Mar-08, Volume: 70, Issue:16
Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1.
AID520085Antimicrobial activity against acrAB-deficient Escherichia coli TG1 harboring plasmid pEX19Gm by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID405084Activity of Citrobacter freundii PER2 beta lactamase2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Biochemical characterization of PER-2 and genetic environment of blaPER-2.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID373068Antimicrobial activity against Staphylococcus aureus CMCC 26112 after 24 hrs by broth microdilution method2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Design, synthesis and antibacterial activity of novel actinonin derivatives containing benzimidazole heterocycles.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1885905Antibacterial activity against multidrug-resistant Acinetobacter baumannii measured after 16 hrs by microdilution assay2022Journal of medicinal chemistry, 08-11, Volume: 65, Issue:15
Lysine-Tethered Stable Bicyclic Cationic Antimicrobial Peptide Combats Bacterial Infection in Vivo.
AID543430Antimicrobial activity against Escherichia coli XL-1 Blue harboring plasmid CL1920 by disk diffusion method in presence of beta-lactamase inhibitor Sulbactam2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID373320Cytotoxicity against human MCF7 cells after 72 hrs by Alamar Blue assay2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
New transition metal ion complexes with benzimidazole-5-carboxylic acid hydrazides with antitumor activity.
AID519834Antimicrobial activity against aheB deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1209735Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID520790Antibacterial activity against beta-lactamase KPC-2 producing Escherichia coli isolate E1 in presence of Sulbactam by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1209733Binding affinity to mouse OAT3 expressed in CHO cells at 10 to 1000 uM measured over 20 mins2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID373070Antimicrobial activity against Sarcina lutea CMCC 28001 after 24 hrs by broth microdilution method2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Design, synthesis and antibacterial activity of novel actinonin derivatives containing benzimidazole heterocycles.
AID543425Antimicrobial activity against Escherichia coli XL-1 Blue transconjugant harboring beta-lactamase CTX-M-64 by disk diffusion method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1211553Drug uptake in iv dosed Sprague-Dawley rat liver after 5 hrs by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1209736Inhibition of human OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID660265Antimicrobial activity against wild type Escherichia coli expressing AcrAB-TolC efflux pump2012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID543417Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 transconjugant by disk diffusion method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID524593Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolate Kpn-DK2 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID405086Ratio of Kcat to Km of Citrobacter freundii PER2 beta lactamase relative to cephalothin2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Biochemical characterization of PER-2 and genetic environment of blaPER-2.
AID156122Affinity for penicillin binding protein 3 of Escherichia coli UB1005 (DC0) was evaluated.1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Dual-action cephalosporins incorporating a 3'-tertiary-amine-linked quinolone.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID156117Affinity against penicillin binding protein 1a of Escherichia coli UB1005 (DC0) was evaluated.1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Dual-action cephalosporins incorporating a 3'-tertiary-amine-linked quinolone.
AID520084Antimicrobial activity against Escherichia coli TG1 harboring plasmid pEX19Gm by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID373321Cytotoxicity against human A549 cells after 72 hrs by Alamar Blue assay2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
New transition metal ion complexes with benzimidazole-5-carboxylic acid hydrazides with antitumor activity.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1885902Antibacterial activity against multidrug-resistant Pseudomonas aeruginosa BNCC 125486 measured after 16 hrs by microdilution assay2022Journal of medicinal chemistry, 08-11, Volume: 65, Issue:15
Lysine-Tethered Stable Bicyclic Cationic Antimicrobial Peptide Combats Bacterial Infection in Vivo.
AID1211818Drug excretion in human assessed as compound excreted into bile at 2 gm, iv after 24 hrs by T-tube method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID575417Antimicrobial activity against anrB-deficient Listeria monocytogenes EGD-e at 30 ug after 16 hrs by disk diffusion assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID322324Antibacterial activity against Escherichia coli INSRA5924 isolates expressing CTX-M-32 and TEM-1B enzymes by agar dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1211550In vivo intrinsic biliary clearance in iv dosed Sprague-Dawley rat by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1548097Antimicrobial activity against drug-resistant Escherichia coli clinical isolates assessed as inhibition of microbial growth incubated for 16 hrs by microdilution method2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Novel Stapling by Lysine Tethering Provides Stable and Low Hemolytic Cationic Antimicrobial Peptides.
AID520792Antibacterial activity against Escherichia coli EC600 transconjugant harboring beta-lactamase KPC-2 in presence of Sulbactam by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID155833The compound was evaluated for the inhibition of [14C]- Pen G binding to Escherichia coli UB1005 PBP2 66 kDa.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Dual-action cephalosporins: cephalosporin 3'-quinolone carbamates.
AID325446Antibacterial activity against Salmonella enterica serovar Typhimurium LT2 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID1548096Antimicrobial activity against Pseudomonas aeruginosa assessed as inhibition of microbial growth incubated for 16 hrs by microdilution method2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Novel Stapling by Lysine Tethering Provides Stable and Low Hemolytic Cationic Antimicrobial Peptides.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID521425Antibacterial activity against Stenotrophomonas maltophilia isolate KJ by Etest2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID520082Antimicrobial activity against aheB deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring AheABC efflux pump by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1885896Antibacterial activity against Pseudomonas aeruginosa BNCC 125486 measured after 16 hrs by microdilution assay2022Journal of medicinal chemistry, 08-11, Volume: 65, Issue:15
Lysine-Tethered Stable Bicyclic Cationic Antimicrobial Peptide Combats Bacterial Infection in Vivo.
AID567581Antimicrobial activity against Acinetobacter baumannii assessed as susceptible isolate by broth dilution method in presence of beta-lactamase inhibitor Sulbactam2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID562222Antimicrobial activity against Desulfovibrio desulfuricans Essex 6 by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Susceptibilities of 23 Desulfovibrio isolates from humans.
AID562229Antimicrobial activity against Desulfovibrio desulfuricans MB in presence of Sulbactam by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Susceptibilities of 23 Desulfovibrio isolates from humans.
AID155941Concentration required for 90% inhibition of [14C]-pen G binding1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Dual-action cephalosporins incorporating a 3'-tertiary-amine-linked quinolone.
AID679146TP_TRANSPORTER: uptake in Xenopus laevis oocytes2002Drug metabolism and pharmacokinetics, , Volume: 17, Issue:2
Rat renal organic anion transporter rOAT1 mediates transport of urinary-excreted cephalosporins, but not of biliary-excreted cefoperazone.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1211551Drug uptake in sandwich cultured Sprague-Dawley rat hepatocytes by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID519833Antimicrobial activity against Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method in presence of 64 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID322323Antibacterial activity against Escherichia coli DH5 alpha-URA5905 isolates expressing CTX-M-15 and TEM-1B enzymes by agar dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID373069Antimicrobial activity against Klebsiella pneumoniae CMCC 46117 after 24 hrs by broth microdilution method2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Design, synthesis and antibacterial activity of novel actinonin derivatives containing benzimidazole heterocycles.
AID562221Antimicrobial activity against Desulfovibrio fairfieldensis by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Susceptibilities of 23 Desulfovibrio isolates from humans.
AID1211802Drug excretion in iv dosed rat assessed as compound excreted into bile2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1885887Antibacterial activity against methicillin-resistant Staphylococcus aureus BNCC 186335 measured after 16 hrs by microdilution assay2022Journal of medicinal chemistry, 08-11, Volume: 65, Issue:15
Lysine-Tethered Stable Bicyclic Cationic Antimicrobial Peptide Combats Bacterial Infection in Vivo.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID520083Antimicrobial activity against aheB-deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring AheABC efflux pump by agar dilution method in presence of 64 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID1885884Antibacterial activity against Staphylococcus aureus BNCC 186335 measured after 16 hrs by microdilution assay2022Journal of medicinal chemistry, 08-11, Volume: 65, Issue:15
Lysine-Tethered Stable Bicyclic Cationic Antimicrobial Peptide Combats Bacterial Infection in Vivo.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID567578Antimicrobial activity against Acinetobacter baumannii assessed as resistant isolate by broth dilution method in presence of beta-lactamase inhibitor Sulbactam2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.
AID575340Antimicrobial activity against Listeria monocytogenes EGD-e at 30 ug after 16 hrs by disk diffusion assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics.
AID155840The compound was evaluated for the inhibition of [14C]- Pen G binding to Escherichia coli UB1005 PBP3 60 kDa.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Dual-action cephalosporins: cephalosporin 3'-quinolone carbamates.
AID1885899Antibacterial activity against multidrug-resistant Escherichia coli BNCC 133264 measured after 16 hrs by microdilution assay2022Journal of medicinal chemistry, 08-11, Volume: 65, Issue:15
Lysine-Tethered Stable Bicyclic Cationic Antimicrobial Peptide Combats Bacterial Infection in Vivo.
AID322320Antibacterial activity against Escherichia coli INSRA5776 isolates expressing CTX-M-14 and TEM-1B enzymes by agar dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID543414Antimicrobial activity against Shigella sonnei UIH-1 expressing beta-lactamase CTX-M-64 by disk diffusion method in presence of beta-lactamase inhibitor Sulbactam2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID680340TP_TRANSPORTER: inhibition of PAH uptake in Xenopus laevis oocytes2002Drug metabolism and pharmacokinetics, , Volume: 17, Issue:2
Rat renal organic anion transporter rOAT1 mediates transport of urinary-excreted cephalosporins, but not of biliary-excreted cefoperazone.
AID562223Antimicrobial activity against Desulfovibrio desulfuricans MB by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Susceptibilities of 23 Desulfovibrio isolates from humans.
AID520087Antimicrobial activity against acrAB-deficient Escherichia coli TG1 harboring AheABC efflux pump by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID1211548In vivo apparent biliary clearance in iv dosed Sprague-Dawley rat by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1219873Inhibition of recombinant human ABCC2 expressed in insect Sf21 cell plasma membrane vesicles assessed as inhibition of transporter-mediated [3H]-estradiol-17beta-glucuronide uptake by liquid scintillation counting analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Oral availability of cefadroxil depends on ABCC3 and ABCC4.
AID156119Affinity for penicillin binding protein 1b of Escherichia coli UB1005 (DC0) was evaluated.1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Dual-action cephalosporins incorporating a 3'-tertiary-amine-linked quinolone.
AID679364TP_TRANSPORTER: inhibition of Salicylate uptake (salicylate: 1 uM, Cefoperazone: 1000 uM) in Xenopus laevis oocytes1998FEBS letters, Jun-12, Volume: 429, Issue:2
Identification of multispecific organic anion transporter 2 expressed predominantly in the liver.
AID325443Antibacterial activity against Escherichia coli K10 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID543413Antimicrobial activity against Shigella sonnei UIH-1 expressing beta-lactamase CTX-M-64 by disk diffusion method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID543429Antimicrobial activity against Escherichia coli XL-1 Blue harboring plasmid CL1920 by disk diffusion method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID155829The compound was evaluated for the inhibition of [14C]- Pen G binding to Escherichia coli UB1005 PBP1a 90 kDa.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Dual-action cephalosporins: cephalosporin 3'-quinolone carbamates.
AID1211552In vitro intrinsic biliary clearance in sandwich cultured Sprague-Dawley rat hepatocytes by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1211870Total biliary clearance in iv dosed rat2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID156120Affinity for penicillin binding protein 2 of Escherichia coli UB1005 (DC0) was evaluated.1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Dual-action cephalosporins incorporating a 3'-tertiary-amine-linked quinolone.
AID322319Antibacterial activity against Escherichia coli DH5 alpha isolates by agar dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1219874Inhibition of recombinant human ABCC3 expressed in baculovirus infected insect Sf21 cell plasma membrane vesicles assessed as inhibition of transporter-mediated [3H]-estradiol-17beta-glucuronide uptake by liquid scintillation counting analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Oral availability of cefadroxil depends on ABCC3 and ABCC4.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID520088Antimicrobial activity against Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID681006TP_TRANSPORTER: inhibition of Glutarate uptake (Glutarate: 5 uM, Cefoperazone: 1000 uM) in Xenopus laevis oocytes2002Molecular pharmacology, Jul, Volume: 62, Issue:1
Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice.
AID543422Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 by disk diffusion method in presence of beta-lactamase inhibitor Sulbactam2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID1209734Inhibition of mouse OAT1 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID521434Antibacterial activity against Stenotrophomonas maltophilia isolate KJ deficient in L1 beta lactamase gene at 16 ug/ml2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID1211837Total biliary clearance in human at 2 gm, iv after 24 hrs by T-tube method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID681569TP_TRANSPORTER: inhibition of Estrone sulfate uptake in OAT4-expressing S2 cells2002European journal of pharmacology, Mar-08, Volume: 438, Issue:3
Interaction of human organic anion transporters with various cephalosporin antibiotics.
AID322322Antibacterial activity against Escherichia coli INSRA5905 isolates expressing CTX-M-15 and TEM-1B enzymes by agar dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID520086Antimicrobial activity against acrAB-deficient Escherichia coli TG1 harboring AcrAB efflux pump by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID325448Antibacterial activity against Staphylococcus aureus Mu50 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID681377TP_TRANSPORTER: inhibition of PAH uptake in OAT1-expressing S2 cells2002European journal of pharmacology, Mar-08, Volume: 438, Issue:3
Interaction of human organic anion transporters with various cephalosporin antibiotics.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID681435TP_TRANSPORTER: inhibition of E1S uptake (E1S: 40 uM, Cefoperazone: 1000 uM) in Xenopus laevis oocytes1999The Journal of biological chemistry, May-07, Volume: 274, Issue:19
Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681363TP_TRANSPORTER: inhibition of PAH uptake in OAT1-expressing S2 cells2002Life sciences, Mar-08, Volume: 70, Issue:16
Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1.
AID543418Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 transconjugant by disk diffusion method in presence of beta-lactamase inhibitor Sulbactam2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID322325Antibacterial activity against Escherichia coli DH5 alpha-URA5924 isolates expressing CTX-M-32 by agar dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID1211549Unbound fraction in Sprague-Dawley rat plasma at 100 uM by equilibrium dialysis method2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID520787Antibacterial activity against beta-lactamase KPC-2 producing Serratia marcescens isolate S1 to S21 in presence of Sulbactam by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID322321Antibacterial activity against Escherichia coli DH5 alpha-URA5776 isolates expressing CTX-M-14 enzyme by agar dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID519734Antibacterial activity against Escherichia coli DH5alpha with deltaampC by agar dilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID520791Antibacterial activity against Escherichia coli EC600 in presence of Sulbactam by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID1548093Antimicrobial activity against methicillin-resistant Staphylococcus aureus assessed as inhibition of microbial growth incubated for 16 hrs by microdilution method2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Novel Stapling by Lysine Tethering Provides Stable and Low Hemolytic Cationic Antimicrobial Peptides.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1803292Glutathione Reductase Activity Assay from Article 10.3109/14756366.2012.688042: \\Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione S-transferase to different antibiotics: in vitro approach.\\2013Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 28, Issue:4
Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione S-transferase to different antibiotics: in vitro approach.
AID1803294Glutathione Peroxidase Activity Assay from Article 10.3109/14756366.2012.688042: \\Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione S-transferase to different antibiotics: in vitro approach.\\2013Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 28, Issue:4
Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione S-transferase to different antibiotics: in vitro approach.
AID1803293Glutathione S-transferase Activity Assay from Article 10.3109/14756366.2012.688042: \\Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione S-transferase to different antibiotics: in vitro approach.\\2013Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 28, Issue:4
Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione S-transferase to different antibiotics: in vitro approach.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,202)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990630 (52.41)18.7374
1990's218 (18.14)18.2507
2000's130 (10.82)29.6817
2010's150 (12.48)24.3611
2020's74 (6.16)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 94.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index94.85 (24.57)
Research Supply Index7.30 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index173.94 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (94.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials167 (12.80%)5.53%
Reviews42 (3.22%)6.00%
Case Studies123 (9.43%)4.05%
Observational1 (0.08%)0.25%
Other972 (74.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of Cefoperazone Sodium and Sulbactam Sodium Combination (1/1 g/Vial) After Intravenous Infusion of 1 g Cefoperazone Sodium and 1 g Sulbactam Sodium in Health [NCT05654090]Phase 414 participants (Anticipated)Interventional2022-08-25Active, not recruiting
Randomized Controlled Trial of Antibiotic Prophylaxis in Rectal Cancer Surgery: Oral With Intravenous Versus Intravenous Antibiotics. [NCT03436719]280 participants (Anticipated)Interventional2017-11-06Recruiting
The Effect of Nebulization of Alkaline Solution on Treating Extensively Drug Resistant A. Baumannii Pneumonia With Cefoperazone and Sulbactam Plus Minocycline: A Multi-center Randomized Study [NCT02060149]Phase 1/Phase 290 participants (Anticipated)Interventional2014-03-31Not yet recruiting
Epidemiological Study on Drug-induced Coagulation Disorder Caused by Cefoperazone Sulbactam Sodium and Construction of Prediction Model [NCT05535309]8,000 participants (Anticipated)Observational2021-11-02Active, not recruiting
Escalade or Deseacalade Antibiotic Use in Severe Acute Pancreatitis [NCT01992198]Phase 460 participants (Anticipated)Interventional2012-07-31Recruiting
Phase Ⅱ Study on Ceftazidime Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection [NCT01601093]Phase 2288 participants (Anticipated)Interventional2011-11-30Suspended(stopped due to other project got priority)
Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections In Slovakia. An Open, Prospective, Non-Comparative Study. [NCT00463762]0 participants (Actual)Observational2007-05-31Withdrawn
A Randomized, Open Label, Multicentre Phase Iv Study To Evaluate The Efficacy And Safety Of Magnex (Cefoperazone-Sulbactam) In Comparison With Ceftazidime Plus Amikacin And Metronidazole In The Treatment Of Intra-Abdominal Infections [NCT00360607]Phase 4307 participants (Actual)Interventional2004-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]